Theragen

Executive Summary

Theragen is a San Diego-based medical device company founded in 2017, developing the ActaStim® bone growth stimulator system—a non-invasive, wearable device intended to improve spinal fusion success rates through electrical stimulation. Currently in the preclinical stage, the company has not yet initiated clinical trials or obtained FDA clearance. Given the early stage, the primary focus is on advancing the technology through regulatory and clinical milestones. The company operates at the intersection of neuroscience and medical devices, targeting a significant unmet need in spinal fusion, where non-union rates remain high. While Theragen's technology shows promise, the lack of clinical data and regulatory progress presents substantial risk. The company's ability to secure funding and execute on its development plan will be critical to near-term viability. The executive summary is based on limited public information, and the conviction score reflects the early-stage nature and absence of validated clinical or commercial traction.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Submission for ActaStim30% success
• Q1 2027Series A Funding Round40% success
• Q2 2027Initiation of First Clinical Trial25% success